Church & Dwight (CHD) Q2 2025 earnings review
Growth Stalls and Q3 Guidance Disappoints Amid Portfolio Overhaul
Church & Dwight's growth engine stalled in Q2, posting flat (+0.1%) organic sales after a negative Q1. While adjusted EPS of $0.94 beat the company's lowered outlook, this was overshadowed by a weak forecast for Q3, which projects a 9% YoY decline in EPS. The core U.S. consumer business remains in decline (-1.0% organic), and the critical Vitamin segment continues to collapse, prompting a formal strategic review. Management is actively reshaping the portfolio by acquiring high-growth Touchland while exiting three lower-margin businesses, but underlying margin pressures from tariffs and inflation are intensifying, signaling a challenging second half.
🐂 Bull Case
Management is taking decisive action, acquiring the fast-growing Touchland hand sanitizer brand while exiting three lower-margin, tariff-exposed businesses (Flawless, Spinbrush, Waterpik showerheads) to improve the long-term growth profile.
Recent acquisitions HERO and THERABREATH continue to be standout performers, with consumption growth of +11.4% and +22.5% respectively. They are gaining significant market share and provide a powerful offset to weakness elsewhere.
The International segment delivered another solid quarter with 4.8% organic growth, providing crucial diversification and growth as the core U.S. market struggles.
🐻 Bear Case
The forecast for a 9% YoY decline in Q3 Adjusted EPS points to severe margin pressure. This suggests that cost headwinds are accelerating and will more than erase the benefit from a slight recovery in sales growth.
The vitamin business is a major drag, with consumption down ~25%. The launch of a strategic review, including a potential divestiture, signals internal turnaround efforts have failed and could lead to a dilutive exit.
The U.S. consumer business, the company's largest segment, posted a 1.0% organic sales decline. This marks the second consecutive quarter of negative growth, indicating persistent weakness in the core portfolio.
⚖️ Verdict: 🔴
Bearish. While the Q2 EPS beat offers a glimmer of positive execution, it is overshadowed by the fundamental challenges. The core domestic business is weak, the high-margin vitamin segment is collapsing, and the -9% Q3 EPS guidance is a significant red flag for profitability. The portfolio moves are sound long-term, but the near-term outlook is dominated by margin pressure and operational struggles.
Key Themes
Vitamin Business Collapse Forces Strategic Review
The gummy vitamin business has deteriorated from a drag into a crisis. Management reported that consumption was down approximately 25% in the quarter, a sharp underperformance versus a category that grew almost 4%. This failure prompted the company to launch a formal strategic review, considering options from a divestiture to a JV or a radical streamlining of the business. This move concedes that the turnaround plan is not working and creates significant uncertainty around the future of this segment.
Margin Pressure Intensifies, Driving Weak Q3 Outlook
Profitability is a primary concern. After a 40 bps YoY contraction in Q2 adjusted gross margin, management guided to a much sharper 100 bps contraction for Q3. The drivers are persistent inflation, tariff costs, and the dilutive effect of the businesses being exited. This margin pressure is the direct cause of the -9% Q3 adjusted EPS guidance, indicating that cost headwinds are outpacing pricing and productivity efforts.
Portfolio Pruning and Bolt-on Acquisition
Management is actively reshaping its portfolio to focus on growth. The company closed its acquisition of Touchland, the #2 and fastest-growing hand sanitizer brand, adding an eighth 'power brand'. Simultaneously, it is exiting the FLAWLESS, SPINBRUSH, and WATERPIK showerhead businesses. This strategy aims to shed lower-margin, tariff-sensitive assets while adding a high-growth, on-trend brand to the portfolio, which should improve the company's long-term growth algorithm.
U.S. Domestic Business Remains Weak
The core Consumer Domestic segment, which represents over 75% of sales, continues to struggle, posting a 1.0% organic sales decline. Trend is reversing/negative. While this is an improvement from Q1's -3.0% decline, which was heavily impacted by retailer destocking, the segment has not yet returned to growth. Strength in International (+4.8%) is masking persistent softness in the company's primary market.
HERO and THERABREATH Continue to Outperform
Despite the broader slowdown, the company's key growth acquisitions continue to deliver. THERABREATH consumption grew 22.5% in a down mouthwash category, solidifying its #2 brand position with 21% share. HERO outpaced the acne category with 11.4% consumption growth and remains the #1 brand at 22% share. Management continues to highlight the low household penetration of these brands as a long-term runway for growth.
Macro Environment Stabilizing but Uncertain
Management noted that category consumption trends, which turned negative in early April, improved sequentially through Q2. This observation provides the confidence to maintain the full-year organic growth outlook of 0-2%. However, they still characterize the environment as uncertain, and the weak Q3 profit guidance suggests significant cost pressures persist despite stabilizing consumer demand.
Other KPIs
The company recorded significant charges related to its decision to exit the FLAWLESS, SPINBRUSH, and WATERPIK showerhead businesses. These charges, primarily non-cash impairments, were excluded from adjusted earnings but reduced reported EPS from an adjusted $0.94 to $0.78.
Cash from operations declined by $83.4 million compared to the first half of 2024. The decrease was attributed to lower cash earnings and unfavorable timing of working capital. The company maintained its full-year outlook of approximately $1.05 billion, implying a significant improvement in the second half.
The company executed a $300 million accelerated share repurchase (ASR) program during the quarter, signaling a commitment to returning capital to shareholders despite operational challenges.
Guidance
Decelerating Sharply. This guidance implies a 9% decline from last year's adjusted Q3 EPS of $0.79. The drop is driven by a forecasted 100 basis point contraction in adjusted gross margin and higher marketing investments, which will more than offset the expected sales growth.
Accelerating. The midpoint of 1.5% represents a sequential acceleration from Q2's +0.1% and Q1's -1.2%. This suggests management sees the worst of the retailer destocking and consumer pullback as being over, with a slow recovery underway.
Stable but lowered. This guidance was maintained from the significant reduction made in Q1. Holding the full-year outlook steady despite the weak Q3 EPS forecast implies the company expects a very strong Q4 performance, both in sales and, more critically, in margin recovery.
Stable. The company reiterated its expectation for a 60 basis point contraction for the full year. Key headwinds cited are tariffs, elevated input costs, and unfavorable product mix, which are expected to outweigh productivity gains.